Aurobindo receives FDA ok for perindopril and escitalopram
This article was originally published in Scrip
Executive Summary
Aurobindo Pharmahas received tentative approvals from the US FDAfor perindopril erbumine tablets 2mg, 4mg and 8mg, generic versions ofSolvay Pharmaceuticals' antihypertensive, Aceon, and for escitalopram oxalate oral solution 5mg (base)/5ml, a generic version ofForest Laboratories' antidepressant, Lexapro. Aurobindo has received 85 ANDA approvals from the FDA, which include 61 final approvals and 24 tentative approvals.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.